October 18th-20th 2022

11th EPP Life Sciences Pricing Forum

11th EPP Life Sciences Pricing Forum

Redefining Life Sciences Pricing Strategies for Sustainable Post-Pandemic Growth

IN-PERSON EVENT

The must-do pricing conference

30+ Speakers
98% Attendee satisfaction
100% Networking

11th EPP Life Sciences Pricing Forum

We are very excited to introduce you to this year’s annual conference, packed with outstanding speakers eager to share with you all the key trends, forecasts, and best practices in pricing, reimbursement, market access, and tendering across the Pharmaceutical, MedTech, and Biotech industries. This in-person event will provide you with ample opportunity and time to network face-to-face with your peers.

Under the last forum’s theme Redefining Life Sciences Pricing Strategies for Sustainable Post-Pandemic Growth, we are devoting this best-in-class conference (with Pharma and MedTech dedicated tracks beside the plenary) to the main issues, challenges, and trends impacting the pricing, revenue, reimbursement and market access professionals in the Life Sciences industry.

Key Programme Sessions of 2022:

  • Latest pricing trends to drive commercial success and enhanced patient access
  • Unlocking Value Through Evidence, Collaboration & Transparency
  • Embracing new business models for the digital era
  • Confronting uncertainty and thriving in times of global upheaval

With renowned pricing and revenue decision-makers in attendance, this is the premier event of its kind.

The EPP Life Sciences Pricing Forum is an exclusive thought leadership conference for

  • Global pricing and market access executives,
  • Directors of global pricing and pricing process excellence,
  • Commercial excellence, pricing, reimbursement and tender specialists, market access managers,
  • Marketing and sales directors of Pharmaceuticals, MedTech, and Biotech companies

This forum will provide the most interactive and pioneering discussions in the form of workshops, expert presentations, panel sessions, roundtable discussions, and great networking activities. You will be able to discuss pricing and market access challenges, stakeholder relationships discover innovative tools and solutions for the ecosystem.

Download the brochure

Are you a healthcare industry pricing professional and would you like to share your expertise? 

Please contact Elisa Arias at elisa.arias@pricingplatform.com

11th EPP Life Sciences Pricing Forum

Pre-order the brochure now for the speaker line-up, agenda and more

Get the brochure sent to your inbox


First name*
Last name*
Company
Email*
Telephone

Programme

October 18th 2022

Skip to next day

WORKSHOPS

Designing a price strategy

Workshop facilitator: Alan Crowther, General Manager, Global Pricing & Access Solutions, Eversana

A detailed presentation and hands-on series of exercises for developing a price strategy for products in a variety of situations. Review of key elements of a pricing strategy, methodologies for developing, and key analytic techniques for ensuring robustness of pricing strategies.

  • Designing a launch price strategy
    • Design methodology
    • Key components and needs
    • Pressure testing a strategy
      • Sensitivity analysis
      • Analogue benchmarking
  • Managing In-Line Pricing Strategy
    • (re) designing an in-line price strategy on indication expansion or acquisition/in-license of a mature product
    • Monitoring techniques for in-line price strategies

 

The Growing Dynamics of Global Tender Management

Workshop facilitators: Peter Zimmermann, Senior Director, Professional Services, Model N & Carl Lonsdale, Senior Solutions Consultant, Model N & Ruven Remo Eul, Principal – Life Sciences, Marbls

Tenders continue to be an increasingly important revenue stream for Life Sciences companies. Pharma and Medtech companies who learn how to make the most of tender opportunities, while streamlining processes to compete effectively, have the most to win from successful tender management strategies.

Leveraging the combined experience of the workshop experts, we will cover the following topics:

  • Learn how increasing visibility into tender opportunities can optimize the tender management process
  • See how successful organizations are leveraging tender intelligence and reporting
  • Learn about Deal Calculator to optimize your tender proposals and pricing

Beyond Price Management: A 3-step Guide for reaching the peak in Revenue Management

Workshop facilitator: Alejandra Garitonandía, Industry Principal EMEA, Vistex

Margin Management – or the ability to understand where money is made and lost in your business- is critical nowadays for any life sciences company success but to get this information, and more important to get the control of it, is difficult and takes time.

Based on the EPP Though Leadership “Tacking the Pharma Path for Optimizing Revenue Streams” we’ll analyse how we can drive our company to increase the sales margin by just doing corrections on revenue leakages, increasing sales or generating new sources of revenue.

Join us on this working to find out “what’s next” in the Revenue Management Journey and how to reach the next tier on the Revenue Management Excellence Roadmap.

Your perfect tender excellence journey

Workshop facilitator: George Boretos, Co-Founder and Co-CEO, Cube RM

Using the combined experience and know-how of the participants & experts to jointly develop the perfect tender excellence journey:

  • 7 steps for success in tendering
  • Developing the ideal tender excellence process leveraging new technologies
  • Prioritise the key elements & actions to optimise your tendering business

October 19th 2022

Skip to next day

SESSION 1 – Latest pricing trends to drive commercial success and enhanced patient access

08.30

Welcome by EPP President

Pol Vanaerde - President, EPP - Pricing Platform

08.35

Chairman’s Opening Remarks

Ian Tidswell - Founder & Lead Consultant - een Consulting GMBH

8.45

Opening Keynote Address: The Future of Pricing Across the Product Lifecycle

Alan Crowther - General Manager, Global Pricing & Access Solutions - Eversana

A review of critical pricing trends and key insights on where pricing is going in Life Sciences across the entire product lifecycle, from early stage through launch and the end of the product lifecycle.

9.15

Interactive Panel Discussion: Achieving Pricing and Market Access excellence through organisational and operational optimisation

Astrid Buys - Global Head of Pricing - Vifor Pharma & Benoît Donze - Director, EU Pricing & Reimbursement Lead - Amarin Corporation & Libor Minichbauer, Executive Director Global Pricing - Oncology Global Value & Access, Novartis

  • Building the pricing team of the future: assessing how to design an organisational structure suited to strategic priorities and goals
  • Boosting the cooperation between P&MA teams on the global and regional level – tools and approaches to foster collaboration in an efficient way
  • Empowering and aligning pricing and commercial teams to enable optimisation and drive growth
  • Enhancing operational effectiveness by developing an optimal pricing governance
  • Attracting talent and building a career in pricing and market access – is it always a ‘next career move’ or a C-level position the long-term prospects for pricing professionals?

Healthcare is facing a shifting industry paradigm – accelerated digitization, siloed data, heightened competition and other disruptions are putting pressure on pharmaceuticals, MedTech, and biotech companies. Are you successfully adapting your commercial model for the post-pandemic healthcare ecosystem? Chris Kennedy-Sloane illustrates how you can embrace the accelerated digital shift in MedTech by aligning your people, processes, and technologies and adopting value-based marketing and messaging. Attend to learn how to:

  • Build a next-generation commercial excellence model
  • Make the most of your data and integrate it into the price setting and management process
  • Manage complex and ever-growing portfolios of products and prices
  • Create internal alignment and guide your sales team
11.00

PHARMA BREAKOUT: Pricing and Reimbursement of Gene Therapies

Axel Boehnke - Director Market Access Europe North - PTC Therapeutic

Epidemiology, evidence and benefit-rating – do we have a knowledge-problem regarding Gene Therapies?

  • Criteria to monetarily assess Gene Therapies – do we have an assessment-problem with Gene Therapies?
  • Fair Reimbursement-models – do we have a pricing-problem with Gene Therapies?
11.00

MEDTECH BREAKOUT: The value of competitive pricing intelligence

Loon Lee Spielmann - Commercial Policy Director, eCommerce and Indirect Channels - Philips

  • What is the acceptance of value-based pricing/selling in your organization?
  • What is the role of competition in your pricing practices?
  • How do you acquire and process competitive knowledge and leverage it for pricing?

It is fundamental to identify the sources of pricing data and their limitations: within the organization vs external.

At the same time, information should be structurally processed to generate insights, without turning it into a reporting activity.

This can be done by:

  • Identifying sources of data and using a crowdsourcing approach to acquire knowledge
  • Managing unstructured data with high level of uncertainties
  • Putting data together to generate insights
  • Convincing top management to become advocate for the project
  • Ensuring countries’ adhesion to the project
  • Developing an effective communication plan
11.30

MEDTECH BREAKOUT: Developing optimal market access strategies for advanced moleculardiagnostic technologies

Benjamin Gannon - Head of International Access & Policy - Guardant Health

  • Analysing current pricing and reimbursement systems for advanced diagnostics. Should Value Based Pricing be applied?
  • Understanding main barriers for reimbursement internationally – are they restraining the growth of innovation in advanced diagnostics?
  • Case study: reimbursement of ctDNA testing in advanced cancers in Europe

SESSION 2 – Unlocking Value Through Evidence, Collaboration & Transparency

13.00

Keynote Presentation: Demonstrating value and optimising access through evidence and collaboration

Sandro Cesaro - Head of Market Access & Innovative Value Strategies - Oncology Europe, AstraZeneca

  • Assessing the fast development of the EU Joint HTA programme. What are the implications for market access and pricing in the long term? How will this shared effort deliver meaningful value for patients by securing opportune access to innovative medicines?
  • Exploring the key role of Real-World Evidence (RWE) research in value-based pricing. How are Pharma companies using RWE to facilitate the use of value-based contracts with payers for high-cost medicines? How has the pandemic stressed the power and value of real-world data?
  • Next-generation RWE: Maximising value from RWE generation with advanced analytics
  • Analysing the influence of patient-reported outcome data from clinical trials (PROs) on policymakers, regulators, and payers to support drug approval, pricing, and reimbursement decisions
  • What capabilities and technologies should be harnessed to tackle the challenging match between value and costs?
  • Ensure collaboration and alignment among country, region, and global teams – as well as among pricing, market access, supply chain, and finance functions.
  • Leverage sophisticated tools to make informed decisions regarding launch and in-market strategies and execution.
  • Gain a deep understanding of your competitors’ strengths and past behavior in all markets – not just the ones you’re initially targeting.
  • Establish processes and governance.
  • Create a single repository of trusted and reliable information on referencing rules, up-to-date prices, and market access information.
  • Determining the most optimal timing and pricing strategies for a product launch – what’s the optimal launch roadmap for launch success? (price is one element only and in general final approach depends on the strategic goals, environment, etc.)
  • Delving into how companies can assess product launch country specifics and the risk associations
  • Understanding why extensive international reference pricing risk analysis is one of key inputs to successfully implement an optimal global launch sequence and pricing strategy for new medicines
  • Assessing the impact of cost containment environment and payers’ budgetary constraints on our ability to bring innovation to patients from product launch over the lifecycle
15.00

PHARMA BREAKOUT: Assessing the implementation of Health Technology Assessments (HTAs) in Switzerland

Goedele Van Haasteren, Staff Member, Swiss Federal Office of Public Health

  • Legal Constitution of the HTAs in Switzerland
  • Discovering the FOPH HTA Programme
  • Evaluating the lessons Learned
  • Future Plans
15.00

MEDTECH BREAKOUT: Changing pricing mindset in the new macroeconomic reality

András Péntek - Head of International Vision Care Strategy and Pricing - Alcon

15.30

PHARMA BREAKOUT: Exploring the impact of Biosimilar competition on pricing and access

Aneta Skwarlinska - Director, Head of Pricing / Market Access, Europe & Canada - Biogen

  • Reviewing the dynamics of markets to increase access and availability to patients across EU
  • Insights and trends regarding tendering of biosimilars in Europe
  • Analysing how biosimilar medicines can bring better value for healthcare spending
  • Evaluating current biosimilars’ policies in Europe and future trends
15.30

MEDTECH BREAKOUT: Price to value throughout the product lifecycle

Ian Tidswell - Founder & Lead Consultant - een Consulting GMBH

The strategies and tactics needed to price innovative medical devices changes through the product’s lifecycle.  In this presentation, we’ll review the key value and price drivers, from initially understanding value and adoption barriers, to effective ways to ‘cash cow’ more mature and less differentiated products.

16.00

Expert commentary: The Oslo Medicines Initiative: enhancing international collaboration and transparency to boost patient access

Sarah Garner, Senior Policy Advisor, Access to Medicines and Health Products, WHO Regional Office for Europe

  • Understanding how the initiative is propelling collaboration between the public and private sectors to ensure better access to effective, novel, high-priced medicines
  • Two years on – lessons learnt and challenges ahead
  • Learning how the Oslo Medicines Initiative can tackle the ever-increasing prices for medicines and vaccines
16.30

Thought leadership commentary: Why must we develop a customer centric pricing perspective?

Giovanny Leon, Pricing & Access Regional Director - LatAm & Canada, Novartis

  • Do we realize how price components impact the affordability of drugs in Europe?
  • How two neglected pricing policies can help to save costs for HCS and patients
  • Understanding the patient journey toward health care financial roadblocks
  • To acquire a customer-centric price perspective, deep knowledge of the retail price components is necessary
  • Reviewing pharmaceutical price mark-up practice and its implementation
17.00

Closing Keynote address day 1: The journey from value creation to price realization

Gianfranco Parlato, Head of Global Pricing Excellence, Servier

  • an integrated value-based approach…
  • …embedded into the revenue management process
  • Making the impact: organizational challenges
  • Building the infrastructure: key enablers
17.30

Chair’s closing remarks and end of day 1

Ian Tidswell, Founder & Lead Consultant, een Consulting GMBH

October 20th 2022

SESSION 3 – Embracing new business models for the digital era

08.50

Chairman’s Opening Remarks Day 2

Ian Tidswell - Founder & Lead Consultant - een Consulting GMBH

9.00

Keynote Presentation: Overcoming pricing and reimbursement hurdles for Digital Health

Steffen Hartrampf - Vice President, Medical Affairs & Market Access Europe - Kaia Health

  • Addressing main barriers to designing evidence generation plans for Digital Health technologies in order to define a clear reimbursement route
  • New approaches to HTAs for digital products – a feasible strategy?
  • Exploring reimbursement models of digital health apps around Europe: examples in Germany and France
  • What value do digital health solutions bring? What are the funding mechanisms and evaluations?
  • Assessing best pricing models for digital applications in pharma and MedTech
9.30

Expert Commentary: Pricing for tenders: innovative approaches

George Boretos - Co-Founder & Co-CEO - Cube RM

  • Exploring how to win tenders with the right pricing strategy and the key role played by advanced technologies
  • Understanding how to use Tender Analytics to make pricing and budgeting decisions
  • Tender optimisation strategy – what are the latest cost containment strategies and reimbursement?
  • Exploring automatic tender discovery using natural language processing and machine learning
  • Can we anticipate an HTA outcome for any given TPP, using machine learning and why do we need it?
  • Is there a correlation between the HTA outcome and the price? How to connect the dots?
  • Methodology from a case study: Germany
  • Potential next use cases
11.00

PHARMA BREAKOUT: Digital business transformation in Market Access: opportunities and threats

Sebastian Kessel - Head of Market Access & External Engagement Central Europe - UCB

  • Exploring new ways of stakeholder engagements
  • Data generation & analysis: chances of the digital space
  • Taking teams along the digital journey

Multiple factors and events in the recent years have emerged the need for Life Sciences organizations to embrace new business models by leveraging enterprise-wide technology across the globe. As such, companies are planning for and enabling Digital Transformation to support its functions in areas such as contract & price management, tendering, rebates, admin fees and contract compliance to successfully adopt to the new business models, achieving a holistic and digitized competitive advantage.

This session will discuss how companies have reckoned the need for change, achieved internal endorsement, chose leading edge technology and are continuously ensuring its data can drive optimization, as well as planning for accurate levels of people engagement throughout the transformation and beyond to deliver successfully and drive business results.

11.30

PHARMA BREAKOUT: Pricing for Evolutionary Solutions

Andreas Altemark, Head of Global Market Access, Roche Diabetes Care

  • How pricing is different for static products and evolutionary solutions
  • How you get the most out of it for your portfolio
  • Considerations for pricing success
11.30

MEDTECH BREAKOUT: Now and Next in decision making

Alejandra Garitonandía, Industry Principal EMEA, Vistex

No doubts that digitalization is transforming the industry and creating new opportunities but while Analytics and Data Science capabilities are growing very fast there are still yet many companies that are capturing and benefiting only of a small portion of the value.  Data is the backbone in all this process, and it helps us make better decisions and learn from customer and patient behaviours but with all this data comes a problem.

During this session we’ll go through:

  • The advantages of data-driven decision making and how (the right) data can help us to take better decision
  • How the near future looks like?
  • How does AI help in decision making?
  • Roundtable 1 (Pharma): Tender Management: Optimising your tendering process with data and analytics – Facilitator: Gary Watson, EVP,  NAVLIN Software (Eversana)
  • Roundtable 2 (Pharma): External Reference Pricing – Impact of ERP on launch sequencing & patient access – Facilitator: Astrid Buys, Head of Pricing, Vifor Pharma
  • Roundtable 3 (Pharma): Country focused: Development of pricing mechanisms & policies in the USFacilitator: Carl Lonsdale, Sr. Solutions Consultant, Model N
  • Roundtable 4 (MedTech): Shaping and Modelling Optimal Internal Pricing Capabilities, Governance, and Tools in Your Organization – Facilitator: Chris Kennedy-Sloane, Business Consultant, Vendavo
  • Roundtable 5 (MedTech): How to accelerate Pricing & Market Access in Pharma amidst the pressures of a changing environment (inflation, Covid-19, …) Facilitators: Hans Demeyere, Senior Manager Global Pricing, Boehringer Ingelheim & Dominik Barnichon, Senior Manager Global Pricing, Boehringer Ingelheim
  • Roundtable 6 (MedTech): Developing a successful reimbursement strategy 

SESSION 4 – Confronting uncertainty and thriving in times of global upheaval

  • USA: Overview of US drug pricing initiatives, regulatory proposals, potential for implementation in current political environment
  • Canada: New reference countries and new pricing Guidelines
  • Implications of Canadian (and potentially US) international Reference Pricing (IRP)
  • Prospects for Canada – US cross-border trade: myth vs fact
  • National policies and the Biopharmaceutical Ecosystem Index
  • Outlook and implications
14.30

Expert commentary: Advancing MedTech commercial transformation through excellence & innovation in contracting

Anand Sairam, Senior Director - Strategic Pricing & Contract Performance Management Group, BD

  • Industry leading practices across the contracting lifecycle (contract creation, contract execution, monitoring of contract compliance and contract performance/ROI)
  • Moving beyond traditional contracts to innovative value-based contracts
  • Use of AI and automation & tools to drive efficiency and enhanced customer experience
15.00

Interactive Panel Discussion: FutureCast panel: pricing resilience in an unstable political, regulatory, and financial macro environment

Debbie Birch, Commercial Excellence & Strategic Pricing EMEA, BD & George Boretos - Co-Founder & Co-CEO - Cube RM

  • Evaluating key trends that will affect the future of pricing in Life Sciences. What’s the emerging pricing models and strategies to look out for in 2023 and beyond?
  • How is the COVID-19 pandemic long-lasting effect changing the economic strength of the life sciences industry? How is the tender market in the EU evolving in the current post-pandemic climate?
  • How can the Life Sciences pricing professionals harness change and disruption to bolster the role of pricing within the business?
  • Will digital transformation’s acceleration have a real, measurable, attainable impact on pricing and market access in the near future?
  • How will Life Sciences companies achieve commercial success in a context of payer power and post-pandemic cost-containment?
  • What regulatory changes and developments in Europe will shape the pricing and market access industry of the next 5 years?
15.30

Closing Remarks of the Chairman

Ian Tidswell - Founder & Lead Consultant - een Consulting GMBH

15.40

Closing of the Forum by the EPP President – Main Takeaways

Pol Vanaerde - President, EPP - Pricing Platform

Speakers

Alan Crowther

Alan Crowther

General Manager, Global Pricing, Access and Digital Solutions

Eversana

Alan Crowther

Alan Crowther is General Manager, Global Pricing, Access and Digital Solutions at Eversana. He brings 20 years of leadership, consulting and technology experience with him to the position. Alan has previously held roles as CEO at Alliance; founder of Adjility Health, a firm focused on life sciences analytical software; Vice President at Capgemini; Co-founder and Officer at Adjoined Consulting, where he ran the Life Sciences practice and was part of the leadership of the venture-backed company and helped drive it to a successful $200MM+ exit. Prior to Adjoined, Mr. Crowther was head of services for a small software company that exited to BEA Systems; and was a manager at Andersen Consulting (Accenture) before that. He is a graduate of Princeton University.

Alejandra Garitonandia

Alejandra Garitonandia

Life Science Industry Principal EMEA at Vistex

Vistex

Alejandra Garitonandia

Life Sciences passionate and specialized in Revenue Management for Pharma, Background in medical and business educational studies, Broad international experience in different positions in business and IT in Life Sciences, Specialization area is where business processes meet the IT systems and how to support efficient end-to-end revenue management

Anand Sairam

Anand Sairam

Senior Director, Strategic Pricing & Contract Performance Management Group

BD

Anand Sairam

Anand is a senior pricing leader with nearly two decades of professional experience in the med-tech/biopharma sectors across strategic pricing, contracting, marketing, and market access. He currently leads strategic pricing and contract performance management group for the US region at Becton, Dickinson and Company. At BD, he’s responsible for developing strategies to drive ROI, margin and revenue through strategic pricing and profitability management, contracting excellence, value-based contracting, while improving overall customer experience.

He holds a bachelor’s degree in Chemical Engineering and an MBA in Finance and Marketing. He’s also a member of the Professional Pricing Society and have been a regular guest speaker on pricing topics at The Wharton School of Business at the University of Pennsylvania, Columbia Business School at Columbia University and others.

He has co-authored and contributed more than a dozen articles to industry publications such as the Journal of Professional Pricing, Industry Today, Deloitte University Press and Scrip Market Intelligence.

Andras Pentek

Andras Pentek

Head of International Vision Care Strategy and Pricing

Alcon

Andras Pentek

Andreas Altemark

Andreas Altemark

Head of Global Market Access

Roche Diabetes Care

Andreas Altemark

Aneta Skwarlinska

Aneta Skwarlinska

Director, Head of Pricing/ Market Access | Europe & Canada

Biogen Biosimilars

Aneta Skwarlinska

Aneta Skwarlinska is currently heading the Strategic Pricing organization for Biosimilar Business Unit at Biogen. She is in charge of the pricing, tender management and access strategy for already marketed as well as for all future assets to be launched in Europe and Canada. She has broad experience in market access, pricing, tendering and innovating contracting gained at Biogen, MSD, Novo Nordisk and Baxter. Through her career she had an opportunity to work among many therapeutic areas (oncology, infectious diseases, cardiology, immunology, vaccines, diabetes, obesity, haemophilia, biosimilars and others) across different geographies (Europe, Canada, MEA). She is very passionate about unlocking equal patient access to the medicines as well as creating integrated and sustainable solutions for the healthcare system.

Astrid Buys

Astrid Buys

Global Head of Pricing

Vifor

Astrid Buys

Astrid Buys is Global Head of Pricing at Vifor Pharma and has extensive experience with pricing, market access and tenders in the pharmaceutical and medical device industries. Astrid has an international background having lived in six countries throughout Australasia, Europe & Latin America. She holds a master’s degree in Health Economics & Policy from the Barcelona School of Economics.

Axel Boehnke

Axel Boehnke

Director Market Access EU North

PTC Therapeutics

Axel Boehnke

Axel Boehnke is the Director Market Access EU North for PTC Therapeutics.
He´s fully responsible for all market access aspects, Pricing and Reimbursement-issues, Health Technology Assessment, accelerated patient access, early evidence planning, and institutional interactions, focusing on orphan diseases and Gene Therapy. Before, Axel was a Director Market Access at MorphoSys AG, focusing on oncology and especially r/r DLBCL. He has in-depth knowledge and expertise in the specialized business, like Oncology, Autoimmune Diseases, (Ultra) Orphan Diseases, Hepatology, Anti-virals, etc. He also has in track record experience in therapeutic mass markets like cardiovascular or osteoporosis, with respective payer-interactions and contracting.
Axel started with Humira at Abbott in national responsibility, headed the Department of Market Access, managed Care at Servier, and served for experience in the biopharmaceutical industry for the last years. He is a Health Economist (University of Cologne) by education and holds a master’s degree in health and medical management (University Erlangen-Nurnberg). Axel is a member of the German Society of Market Access, the German Society of Health Economics, and the EU Market Access & Value Committee at ARM (Alliance for Regenerative Medicine). He published various articles on Benefit Assessment, Market Access, Healthcare-System Issues, Disease Awareness (i.e. in Rheumatoid Arthritis or Psoriasis), and on Claims-Data-Analysis with Real World Evidence.

Benoît Donze

Benoît Donze

Director, EU Pricing & Reimbursement Lead

Amarin Corporation

Benoît Donze

Dynamic Pharmacist with 10+ years of experience overseeing pricing, contracts & tenders, or public affairs projects within the pharmaceutical industry. Background providing consulting insight regarding pricing and market access. Recognized specialist in defining and implementing commercial offers, as well as serving as contracting specialist for private hospitals and public procurement. Expert in defining and executing strategic plans with influencers across regions. Innovative thinker with demonstrated communication, presentation, and leadership skills; adept at developing creative solutions that maximize efficiency and performance.

Benjamin Gannon

Benjamin Gannon

Head of Int’l Access & Policy ^ Member of the Board, EUCOPE

Guardant Health

Benjamin Gannon

Carl Lonsdale

Carl Lonsdale

Sr. Solutions Consultant

Model N

Carl Lonsdale

Chris Kennedy-Sloane

Chris Kennedy-Sloane

Business Consultant

Vendavo

Chris Kennedy-Sloane

Chris Kennedy-Sloane is a Business Consultant with Vendavo and brings a wealth of pricing and commercial experience across a wide range of areas, including IT, pharmaceuticals, genomics, manufacturing, food and petrochemical industries. Most recently working in industry in the private equity space for LGC group, he drives pricing acceptance and excellence in businesses through creative, realistic solutions that demonstrate real value returns. Prior to Vendavo and LGC group, he ran the Western Digital EMEA pricing function.

Clotilde Noble

Clotilde Noble

Head of Global Pricing and Tenders

Ferring Pharmaceuticals

Clotilde Noble

Clotilde is in charge of the pricing and tendering excellence journey at Ferring Pharmaceuticals. The mission is to secure and ensure implementation of pricing strategies at launch, protect prices in market from erosion by ensuring alignment across countries, regions and global functions to obtain pricing and tendering excellence at a global level. With 10+ years of professional experience in the pharmaceutical industry, she held position within different pharmaceutical companies (Sanofi, Bayer, Ferring) at both affiliate and global level. Scientific by background, she holds a master’s degree in biotechnology and specialized master’s in business and management, she also holds lectures at Grenoble University.

Debbie Birch

Debbie Birch

Commercial Excellence EMEA

BD

Debbie Birch

Dominik Barnichon

Dominik Barnichon

Senior Manager Global Pricing

Boehringer Ingelheim

Dominik Barnichon

Dominik Barnichon, Global Senior Manager Pricing & Contracting with more than 10 years experience in the Pharmaceutical Industry. Driving multiple projects in different roles across affiliates and headquarter functions for Boehringer Ingelheim. Certified Pricing Professional with dedication to strategic and operational success.

Gary Watson

Gary Watson

EVP - NAVLIN Software

Eversana

Gary Watson

George Boretos

George Boretos

Co-Founder & Co-CEO, Cube RM

CubeRM

George Boretos

George Boretos is the co-founder & co-CEO of Cube RM, a vendor of Tender Management software with integrated tender discovery using Natural Language Processing and pricing guidance for tenders using Machine Learning. He has more than 20 years of professional experience in executive leadership positions in product marketing, sales, corporate strategy, and pricing. He is also specializing in predictive pricing guidance & optimization models, with numerous successful business forecasts and scientific publications to his name in prestigious scientific journals and publishers, such as Elsevier and Foresight. He is a member of the International Institute of Forecasters.

Gianfranco Parlato

Gianfranco Parlato

Head of Global Pricing Excellence

Servier

Gianfranco Parlato

Gianfranco is Head of Global Pricing Excellence at Servier. He has 18 years of experience in driving global pricing strategies across industries, mostly human and veterinary pharma, and for major companies, both as an industry leader and as a consultant. He specializes in pricing transformations and governance, building pricing operating models that translate global strategies into effective local empowerment and execution.

Giovanny Leon

Giovanny Leon

Pricing & Access Regional Director - LatAm & Canada

Novartis

Giovanny Leon

Giovanny is a pharmaceutical executive with intensive experience in various management roles in LatAm and the Novartis Global HQ. He is passionate about improving patient access to medicines in two key areas:

1. Shape the market environment to enhance innovation adoption, better understand HCS priorities, and co-create common goals.
2. Drive a customer-centric price perspective to understand how the final prices impact the affordability of HCS and the patient journey toward health care financial roadblocks.

He has an MBA and a Master in Marketing and Commercial Management from Universidad Complutense, Madrid. He has completed several Management & Leadership programs from the University of Cambridge, London Business School, Columbia University, IESA, Universidad de Los Andes, ITAM, ESPM, and IAE.

Goedele van Haasteren

Goedele van Haasteren

Deputy Head of the HTA Department

Federal Office of Public Health

Goedele van Haasteren

Goedele van Haasteren is a Health Technology Assessment (HTA) specialist with profound experience in technology assessment, clinical research and academic teaching. She earned her PhD degree at the Department of Endocrinology, Erasmus University of Rotterdam, the Netherlands (1985-1990). She worked at the University of Geneva (Switzerland) and the Johns Hopkins University in Baltimore (USA). Goedele lives in Bern, Switzerland, where she works as deputy head of the HTA Department of the Federal Office of Public Health in Switzerland since July 2017.

Hans Demeyere

Hans Demeyere

Senior Manager Global Pricing

Boehringer Ingelheim

Hans Demeyere

Hans Demeyere is currently working as Senior Manager Global Pricing at Boehringer Ingelheim. Hans is part of the Pricing & Contracting CoE that delivers capabilities (strategy, process, skills, tools & insights) to BI’ markets & therapeutic areas. Prior to this current engagement, Hans was Director at Monitor Deloitte for more than 10 years.

Ian Tidswell

Ian Tidswell

Founder & Lead Consultant

een Consulting GmbH

Ian Tidswell

Ian Tidswell, PhD, has 15+ years of experience in B2B pricing, both as a consultant and as head of pricing for a $15B Life Sciences company and head of pricing process transformation for a medical device manufacturer. A frequent speaker at B2B and MedTech conferences, Ian brings a practical approach to pricing based on a solid structured approach.

Libor Minichbauer

Libor Minichbauer

Executive Director Global Pricing - Oncology Global Value & Access

Novartis

Libor Minichbauer

Loon Lee Spielmann

Loon Lee Spielmann

Director Commercial Policy & Pricing eCommerce and Indirect Channels

Philips

Loon Lee Spielmann

Loon is a Commercial Policy and Pricing Director with more than 18 years of experience in the healthcare, in-vitro diagnostics and medical devices industry, and previously held positions in product management, marketing and pricing.
His core expertise includes pricing strategies and pricing methodologies, in particular for pricing optimization in solutions, new business models and digitalization.
An area of specialization for Loon is the capability development of competitive pricing intelligence. By leveraging competitive intelligence with pricing analytics, he has led the award winning competitive intelligence program, that helped sales organizations gain advantage against global competitors.

Mirko Ristanovic

Mirko Ristanovic

Sr. Director, Pricing Launch Excellence Lead

Pfizer

Mirko Ristanovic

Neil Palmer

Neil Palmer

Principal Consultant

WN Palmer & Co

Neil Palmer

Neil Palmer is the former CEO of PDCI Market Access Inc. (PDCI), Canada’s leading pricing and reimbursement consultancy he co-founded in 1996. PDCI became a business unit of McKesson Canada in December 2020. Prior to PDCI, Neil worked with the Patented Medicine Prices Review Board (PMPRB) where his responsibilities included policy development, overseeing the price review of patented medicines and conducting economic research. Prior to the PMPRB, he worked with the Health Division of Statistics Canada where he was responsible for economic and statistical analysis of health care costs and utilization. After completing his studies at the University of Western Ontario, Neil began his career in Montreal with the research group of the Kellogg Centre for Advanced Studies in Primary Care. Neil was an Adjunct Assistant Professor at the University of Southern California School of Pharmacy graduate program in Health Care Decision Analysis where he lectured on health technology assessment, pricing and market access from a global perspective. He has presented extensively on pharmaceutical pricing and reimbursement issues and is a frequent speaker at conferences in North America and Europe.

Peter Zimmermann

Peter Zimmermann

Senior Director Professional Services

Model N

Peter Zimmermann

Peter Zimmermann leads Global Customer Success in Europe for Model N, assisting clients with solution definition and project planning to ensure a quick time to value in solving business issues.

Ruven Remo Eul

Ruven Remo Eul

Principal, Life Sciences

Marbls

Ruven Remo Eul

Ruven is a Principal at Marbls based out of Switzerland and has worked close to 15 years in Life Sciences in European and International markets with a primary focus in Pricing, Contracting, Tendering and Commercial Excellence. Ruven began his early career working in industry for Top 5 pharmaceutical manufacturers in tendering, contracting, and commercial effectiveness, from local to global roles. After which, Ruven joined HighPoint Solutions where he started and led consulting services in Europe for Global Pricing and Tender Management. Ruven was responsible for developing teams, creating solutions, and project oversight as well as delivering services across clients from pharma, medical device to biosimilar & generic manufacturers. In addition, he was responsible for managing the international partnerships and Thought Leadership initiatives. Throughout the acquisition by IQVIA, Ruven became in charge of the legacy European HighPoint team. Ruven’s focus continues in Global Pricing & Tender Management as well as Commercial Excellence.

Sandro Cesaro

Sandro Cesaro

Head of Market Access & Innovative Value Strategies, Oncology Europe

AstraZeneca

Sandro Cesaro

Sandro is the Head of Strategic Product Pricing at Roche Pharmaceuticals based in Switzerland.
Sandro has a track record in Pharma, Diagnostics & Consulting for more than 15 years. He brings broad experience in Market Access & Pricing from global, regional and local roles. Before joining Roche Sandro worked as a consultant with a Boston Consulting Group healthcare spin-off. Prior to that Sandro was a scientist in the digital and diagnostics area with IBM Research. Sandro holds a PhD in Biochemistry from the University of Zurich.

Sarah Garner PhD

Sarah Garner PhD

Senior Policy Advisor

WHO Europe

Sarah Garner PhD

Sarah Garner PhD, BPharm is currently the Senior Policy Advisor, Access to Medicines and Health Products, WHO Regional Office for Europe. Sarah is a pharmacist specializing in global access issues and she is responsible for the strategic planning and delivery of policy dialogue and technical support to improve patient access. This includes pharmaceutical systems strengthening, regulation, selection, HTA, pricing and procurement.

Her previous roles have included the Coordinator for the ‘Innovation, Access and Use’ Team in the Essential Medicines and Health Products Department at WHO HQ and the Associate Director for Science Policy and Research at the UK's National Institute for Health and Care Excellence (NICE), and Pharmacist Lead for the UK Government’s Special Advisory Committee on Antimicrobial Resistance.

Dr Sebastian Kessel

Dr Sebastian Kessel

Head of Market Access & External Engagement Central Europe

UCB

Dr Sebastian Kessel

Economist with a PhD in Health Care Management. Consulting Background. Industry Experience in various roles within Market Access: Baxter/Baxalta; SHIRE; Takeda; UCB. Currently heading the Market Access & External Engagement department for Central Europe at UCB.

Steffen Hartrampf, MD

Steffen Hartrampf, MD

Vice President, Head of Medical Affairs & Market Access Europe

Kaia Health

Steffen Hartrampf, MD

Steffen leads Medical Affairs and Market Access Europe at Kaia Health. Kaia Health develops digital applications for MSK and lung diseases. He is responsible for the medical-scientific collaboration with health care professionals and for the market access & reimbursement strategies. He is a pediatrician with many years experience in patient care and research from Ludwigs-Maximilians-University in Munich (Germany) and Memorial Sloan-Kettering Cancer Center in New York (USA). Within his following positions at Bristol-Myers Squibb and at bluebird bio he collaborated with health care professionals and launched innovative drugs in the German market. Since 2021 he is Head of Medical Affairs & Market Access Europe at Kaia Health.

Volkan Beykoz

Volkan Beykoz

Director, Global Pricing – Oncology

Bayer

Volkan Beykoz

Experienced Pricing and Access Leader in the pharmaceuticals industry with strenghts in pricing, value story creation, analytics, problem solving and negotiations with local, regional and global experience. Currently responsible from the global pricing of oncology assets in Bayer focusing on pricing strategy and policy development, price governance and advanced analytics implementation in pharma pricing. Volkan holds a degree in Industrial Engineering and has 15+ years of experience in pricing with 12 years focused in pharmaceutical pricing.

Become a speaker

Full name*

Email*

Company

Message*


Meet top pricing colleagues

This forum attracts a differentiated audience in terms of seniority.

Real diversity

This forum attracts a global audience with a variety of geographies.

Why you should join!

DISCUSS

We stimulate an atmosphere of discussion and interaction, the best way to learn.

LEARN FROM THE BEST

A carefully selected speaking team of top pricing professionals, all active within your industry. No general talk, but only to-the point and useful presentations.

BUILD RELATIONSHIPS

With more than 1000 minutes of network opportunity, you have plenty of time to connect with pricing colleagues from all over Europe.

REFLECT & PRACTICE

Reflect on your key priorities and how to make them really happen! Translate your key learnings into real change.

A word from our attendees

"This is a great conference which covers most pricing topics with a decent amount of detail. Anyone can benefit from this conference no matter how experienced"

Sue Caleo-Naeyaert, Global Head Pricing, Market Access and Policy Biosimilars at Fresenius-Kabi SwissBioSim

"The EPP Life Sciences Pricing Forum is a unique event for learning about the latest pricing challenges and techniques to address them, due to the deep experiences and skills of the participants and speakers"

Ian Tidswell, Founder and Lead Consultant at een Consulting GmbH

"Exciting & an energetic meeting where it is possible to learn, share & discuss best practices and new ideas on hot topics regarding pricing & tendering"

Giuseppe Monita , Senior Manager, Customer Services Contracts & Tendering EMEA at BTG

"A good event for catching up, great networking and opportunity to share current thinking and best practice"

David Alderson, Director at Cogentia Healthcare Consulting

"In my experience, EPP Life Sciences Forum is the only existing opportunity to discuss at 360 degrees about pricing, involving both pharmaceutical and med-tech stakeholders"

Chiara Garavaglia, Partner, Global Leader of Tefen Life Sciences Centre of Excellence & Innovation at Tefen Management Consulting

"A highly recommended forum for pricing professionals"

Henderson Azevedo, Global Pricing Oncology at Bayer

Venue

The Forum will take place at the Renaissance Zurich Tower Hotel. This 5-star boutique hotel enjoys a unique location in the Mobimo Tower, in the trendy Zurich-West district. Many corporate offices and popular clubs like Moods im Schiffbau, Komplex457 and Hive are within walking distance.

The elegant air-conditioned rooms and suites at the Renaissance Zurich Tower Hotel offer floor to ceiling windows providing panoramic views. Other features include flat-screen TVs with Chromecast, and free tea and coffee-making facilities. The hotel also features a gym located on the 15th floor with an impressive view over Zurich.

The Equinox restaurant serves a wide range of dishes and wines. Guests can relax on the summer terrace. Drinks and snacks are available in the Lucid bar. A 24/7 room service is also available.

The railway station Zurich Hardbrücke is 550 yards away providing direct connections to Zurich Central Station with the Zurich Lake and the most famous shopping mile Bahnhofstrasse within 3 minutes. Zurich Airport in Kloten is easy to reach via (S16) within only 11 minutes.

EPP has secured preferential room rate at the Renaissance Zurich Tower Hotel exclusively for the attendees to this Forum. These special room rates include breakfast and tax and would apply up to 3 days before and 3 days after the event dates in case you need to extend your stay.

Accomodation:

EPP has secured a preferential room rate at the Renaissance Zurich Tower Hotel, exclusively for the attendees to this Forum. This special room rate includes breakfast and tax and would apply up to 3 days before and 3 days after the event dates, in case you need to extend your stay.

In order to benefit from this incredible discount, you can book your room directly on this booking link.

Meet pricing decision makers from:

Partners

Platinum partners

Global Prime partners

Global Structural partners

Prime Structural partners

Structural partners

Registration

EPP Members benefit from discounted rates. Not a member yet? Register here.

GROUP DISCOUNT The most popular way to attend – Attend as a team to learn and build company-wide insights!
–> Get -40% on all tickets from 3+ tickets on.

Contact: francisco.porcel@pricingplatform.com

CONFERENCE+WORKSHOP

€1299 €1995


SUPER EARLY BIRD – SAVE BIG

  • SUPER EARLY BIRD – SAVE BIG

  • Access to 4 workshops
  • Access to 2 conference days
  • Coffee break and Lunches for 2 days
  • Access to event networking app (Whova)
  • Network dinner at unique location
  • PDF Speaker presentations after event

Sign up

Our best seller

GROUP BOOKING (MIN. 3) SAVE MIN. € 500/TICKET

€1199 €1995


SUPER EARLY BIRD – SAVE BIG

  • **GROUP BOOKING CONTACT: francisco.porcel@pricingplatform.com**

  • Access to 4 workshops
  • Access to 2 conference days
  • Coffee break and Lunches for 2 days
  • Access to event networking app (Whova)
  • Network dinner at unique location
  • PDF Speaker presentations after event

Contact us


SOLUTION PROVIDER

€2995


  • Access to 2 conference days
  • Coffee breaks and Lunches for 2 days
  • Access to event networking app (Whova)
  • Access to evening event and dinner
  • PDF Speaker presentations after event

Sign up


Once registration is completed, all tickets are transferable but never refundable.